Ibraheem Almani

Brentuximab Vedotin in Severe Systemic Sclerosis: Data on Long-Term Follow-Up and Retreatment

Objectives We previously reported skin and forced vital capacity (FVC) improvements in an open-label clinical trial exploring the use of brentuximab vedotin (BV) in patients with severe diffuse cutaneous systemic sclerosis (dcSSc).[1] Long-term outcomes after therapy was disconti...